glp-1 based therapeutics summit Full Event Guide obesityevents #glp1 | Hanson Wade
Description
doi: 10.1111/bcpt.12962
Eng received a patent for exendin-4 in 1996
Its popularity has been fueled by clinical trials showing that patients taking Ozempic lost an average of 10.9% of their body weight over six months, as well as by the buzz from celebrities, influencers, and everyday conversations
Rybelsus (oral semaglutide) is included in the litigation as well
Can GLP-1 medication cause joint pain
Ongoing Care Ongoing care runs through the patient portal and the Coaching Hub
